FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199068224> ?p ?o ?g. }

• W3199068224 endingPage "79" @default.
• W3199068224 startingPage "67" @default.
• W3199068224 abstract "Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25% to 33%.STIMULI is a 1:1 randomised phase II trial aiming to demonstrate superiority of consolidation combination immunotherapy versus observation after chemo-radiotherapy plus PCI (protocol amendment-1). Consolidation immunotherapy consisted of four cycles of nivolumab [1 mg/kg, every three weeks (Q3W)] plus ipilimumab (3 mg/kg, Q3W), followed by nivolumab monotherapy (240 mg, Q2W) for up to 12 months. Patient recruitment closed prematurely due to slow accrual and the statistical analyses plan was updated to address progression-free survival (PFS) as the only primary endpoint.Of the 222 patients enrolled, 153 were randomised (78: experimental; 75: observation). Among the randomised patients, median age was 62 years, 60% males, 34%/65% current/former smokers, 31%/66% performance status (PS) 0/1. Up to 25 May 2020 (median follow-up 22.4 months), 40 PFS events were observed in the experimental arm, with median PFS 10.7 months [95% confidence interval (CI) 7.0-not estimable (NE)] versus 42 events and median 14.5 months (8.2-NE) in the observation, hazard ratio (HR) = 1.02 (0.66-1.58), two-sided P = 0.93. With updated follow-up (03 June 2021; median: 35 months), median OS was not reached in the experimental arm, while it was 32.1 months (26.1-NE) in observation, with HR = 0.95 (0.59-1.52), P = 0.82. In the experimental arm, median time-to-treatment-discontinuation was only 1.7 months. CTCAE v4 grade ≥3 adverse events were experienced by 62% of patients in the experimental and 25% in the observation arm, with 4 and 1 fatal, respectively.The STIMULI trial did not meet its primary endpoint of improving PFS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in LD-SCLC. A short period on active treatment related to toxicity and treatment discontinuation likely affected the efficacy results." @default.
• W3199068224 created "2021-09-27" @default.
• W3199068224 creator A5000029967 @default.
• W3199068224 creator A5001498932 @default.
• W3199068224 creator A5002623842 @default.
• W3199068224 creator A5002994604 @default.
• W3199068224 creator A5004321308 @default.
• W3199068224 creator A5005673716 @default.
• W3199068224 creator A5005868727 @default.
• W3199068224 creator A5006071350 @default.
• W3199068224 creator A5006078001 @default.
• W3199068224 creator A5008409256 @default.
• W3199068224 creator A5008724268 @default.
• W3199068224 creator A5008914584 @default.
• W3199068224 creator A5010826858 @default.
• W3199068224 creator A5010971455 @default.
• W3199068224 creator A5012411744 @default.
• W3199068224 creator A5013674003 @default.
• W3199068224 creator A5014364032 @default.
• W3199068224 creator A5014938046 @default.
• W3199068224 creator A5015610371 @default.
• W3199068224 creator A5017774297 @default.
• W3199068224 creator A5018218973 @default.
• W3199068224 creator A5018744852 @default.
• W3199068224 creator A5019129337 @default.
• W3199068224 creator A5020866512 @default.
• W3199068224 creator A5021115529 @default.
• W3199068224 creator A5022125986 @default.
• W3199068224 creator A5022806547 @default.
• W3199068224 creator A5022853691 @default.
• W3199068224 creator A5025581681 @default.
• W3199068224 creator A5025910383 @default.
• W3199068224 creator A5027562389 @default.
• W3199068224 creator A5027608149 @default.
• W3199068224 creator A5028953047 @default.
• W3199068224 creator A5028969883 @default.
• W3199068224 creator A5029290817 @default.
• W3199068224 creator A5029588420 @default.
• W3199068224 creator A5033519199 @default.
• W3199068224 creator A5034873604 @default.
• W3199068224 creator A5036032691 @default.
• W3199068224 creator A5037704509 @default.
• W3199068224 creator A5038298950 @default.
• W3199068224 creator A5039079234 @default.
• W3199068224 creator A5039101695 @default.
• W3199068224 creator A5040100064 @default.
• W3199068224 creator A5040451362 @default.
• W3199068224 creator A5040544006 @default.
• W3199068224 creator A5040710721 @default.
• W3199068224 creator A5044439829 @default.
• W3199068224 creator A5045691821 @default.
• W3199068224 creator A5046117778 @default.
• W3199068224 creator A5046277802 @default.
• W3199068224 creator A5046728958 @default.
• W3199068224 creator A5046761240 @default.
• W3199068224 creator A5047402540 @default.
• W3199068224 creator A5047495706 @default.
• W3199068224 creator A5047699624 @default.
• W3199068224 creator A5048231332 @default.
• W3199068224 creator A5050098537 @default.
• W3199068224 creator A5050796727 @default.
• W3199068224 creator A5051086683 @default.
• W3199068224 creator A5052709534 @default.
• W3199068224 creator A5052958356 @default.
• W3199068224 creator A5052962511 @default.
• W3199068224 creator A5054440679 @default.
• W3199068224 creator A5055246540 @default.
• W3199068224 creator A5055480892 @default.
• W3199068224 creator A5056516148 @default.
• W3199068224 creator A5057660841 @default.
• W3199068224 creator A5057674768 @default.
• W3199068224 creator A5059012958 @default.
• W3199068224 creator A5059355812 @default.
• W3199068224 creator A5059969158 @default.
• W3199068224 creator A5062778583 @default.
• W3199068224 creator A5063300526 @default.
• W3199068224 creator A5064610722 @default.
• W3199068224 creator A5065667511 @default.
• W3199068224 creator A5066459779 @default.
• W3199068224 creator A5066952204 @default.
• W3199068224 creator A5070264087 @default.
• W3199068224 creator A5071118692 @default.
• W3199068224 creator A5075203400 @default.
• W3199068224 creator A5075607330 @default.
• W3199068224 creator A5076068129 @default.
• W3199068224 creator A5076548846 @default.
• W3199068224 creator A5077305357 @default.
• W3199068224 creator A5077492791 @default.
• W3199068224 creator A5077576453 @default.
• W3199068224 creator A5078635119 @default.
• W3199068224 creator A5078724283 @default.
• W3199068224 creator A5078912565 @default.
• W3199068224 creator A5080745120 @default.
• W3199068224 creator A5080802514 @default.
• W3199068224 creator A5080841299 @default.
• W3199068224 creator A5082798685 @default.
• W3199068224 creator A5083032364 @default.
• W3199068224 creator A5083786421 @default.

• next